Sakshi Bami1, Anshul Vagrecha2,3, Danielle Soberman3, Mohamad Badawi4, Daniel Cannone5, Jeffrey M Lipton2,3, Randy Q Cron6, Carolyn Fein Levy2,3. 1. Hospitalist Medicine Program, St Jude Children's Research Hospital, Memphis, Tennessee. 2. Department of Pediatrics, Division of Hematology/Oncology and Cellular Therapy, Cohen Children's Medical Center, New Hyde Park, New York. 3. Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York. 4. Division of Pediatric Hematology/Oncology, West Virginia University, Charleston, West Virginia. 5. Division of Pediatric Hematology/Oncology and Stem Cell Transplantation, Children's Hospital of Richmond, Virginia Commonwealth University, Richmond, Virginia. 6. Division of Pediatric Rheumatology, Children's Hospital of Alabama, University of Alabama, Birmingham, Alabama.
Abstract
BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) can be familial or secondary, which is often triggered by infection or malignancy. HLH therapy includes dexamethasone and etoposide. However, therapy is associated with significant morbidity and mortality. Anakinra, a recombinant interleukin-1 receptor antagonist, has been reported to treat macrophage activation syndrome (MAS), rheumatic sHLH. We report our experience with anakinra to treat patients with nonrheumatic secondary HLH (sHLH). PROCEDURE: Six children were diagnosed with HLH from December 2014 to August 2016 and were treated with subcutaneous anakinra (6-10 mg/kg/day divided over four doses) with or without dexamethasone (10 mg/m2 /day). Therapy was either escalated or weaned based on clinical and laboratory response. RESULTS: Five of six patients were treated with anakinra and dexamethasone, and one with anakinra alone due to active cytomegalovirus (CMV) pneumonitis. The median age of diagnosis was 1.8 years (range 0.8-14.9 years). No pathogenic mutations associated with HLH were identified, but three of six possessed genetic variants of unknown significance. Infectious triggers were identified for four patients and two patients had malignancies. The average treatment duration was 8 weeks with 3.5-5.5 years of follow up. No patient needed escalation of therapy to include etoposide. All patients achieved remission. Anakinra was well tolerated without significant adverse effects. CONCLUSION: Initial treatment with anakinra (with or without dexamethasone) is a feasible treatment alternative for patients with secondary HLH and may allow for avoidance of etoposide. We recommend early initiation of anakinra when HLH is suspected. A broader investigation of the use of anakinra as a first-line agent for HLH is ongoing.
BACKGROUND:Hemophagocytic lymphohistiocytosis (HLH) can be familial or secondary, which is often triggered by infection or malignancy. HLH therapy includes dexamethasone and etoposide. However, therapy is associated with significant morbidity and mortality. Anakinra, a recombinant interleukin-1 receptor antagonist, has been reported to treat macrophage activation syndrome (MAS), rheumatic sHLH. We report our experience with anakinra to treat patients with nonrheumatic secondary HLH (sHLH). PROCEDURE: Six children were diagnosed with HLH from December 2014 to August 2016 and were treated with subcutaneous anakinra (6-10 mg/kg/day divided over four doses) with or without dexamethasone (10 mg/m2 /day). Therapy was either escalated or weaned based on clinical and laboratory response. RESULTS: Five of six patients were treated with anakinra and dexamethasone, and one with anakinra alone due to active cytomegalovirus (CMV) pneumonitis. The median age of diagnosis was 1.8 years (range 0.8-14.9 years). No pathogenic mutations associated with HLH were identified, but three of six possessed genetic variants of unknown significance. Infectious triggers were identified for four patients and two patients had malignancies. The average treatment duration was 8 weeks with 3.5-5.5 years of follow up. No patient needed escalation of therapy to include etoposide. All patients achieved remission. Anakinra was well tolerated without significant adverse effects. CONCLUSION: Initial treatment with anakinra (with or without dexamethasone) is a feasible treatment alternative for patients with secondary HLH and may allow for avoidance of etoposide. We recommend early initiation of anakinra when HLH is suspected. A broader investigation of the use of anakinra as a first-line agent for HLH is ongoing.
Authors: Mariusz Matyszewski; Weili Zheng; Jacob Lueck; Zachary Mazanek; Naveen Mohideen; Albert Y Lau; Edward H Egelman; Jungsan Sohn Journal: Nat Commun Date: 2021-05-12 Impact factor: 14.919
Authors: Daniel A Lichtenstein; Fiorella Schischlik; Lipei Shao; Seth M Steinberg; Bonnie Yates; Hao-Wei Wang; Yanyu Wang; Jon Inglefield; Alina Dulau-Florea; Francesco Ceppi; Leandro C Hermida; Kate Stringaris; Kim Dunham; Philip Homan; Parthav Jailwala; Justin Mirazee; Welles Robinson; Karen M Chisholm; Constance Yuan; Maryalice Stetler-Stevenson; Amanda K Ombrello; Jianjian Jin; Terry J Fry; Naomi Taylor; Steven L Highfill; Ping Jin; Rebecca A Gardner; Haneen Shalabi; Eytan Ruppin; David F Stroncek; Nirali N Shah Journal: Blood Date: 2021-12-16 Impact factor: 22.113
Authors: Anshul Vagrecha; Hiren B Patel; Tania Mamdouhi; Suchitra Acharya; Abena Appiah-Kubi; Banu Aygun; Adrianna Vlachos; Lawrence C Wolfe; Jeffrey M Lipton; Randy Q Cron; Carolyn Fein Levy Journal: Pediatr Blood Cancer Date: 2021-01-14 Impact factor: 3.838
Authors: Stuart L Goldstein; Lenar T Yessayan; Kelli A Krallman; Michaela Collins; Stefanie Benoit; Angela Westover; H David Humes Journal: Pediatr Nephrol Date: 2022-07-23 Impact factor: 3.651